FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Samsung Bioepis, a biosimilar subsidiary of Samsung Biologics, said Sunday that it has begun direct sales of its eye disease ...
Sportschosun on MSN
Patients with sudden vision loss, retinal vascular obstruction increased 66% over 10 years... regular
Retinal vascular obstruction is an eye disease that causes vision loss by clogging blood vessels that supply nutrition and oxygen to the retina. According to the Health Insurance Review and Assessment ...
NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening ...
A diabetic woman faced sudden blindness after a tooth extraction. Doctors diagnosed a severe eye infection, metastatic ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.
The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a ...
Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, ...
The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
Artificial intelligence may help improve diabetic retinopathy diagnosis and grading accuracy with little additional cost.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback